KLRS — Kalaris Therapeutics Cashflow Statement
0.000.00%
Last trade - 00:00- $109.04m
- -$9.25m
- 42
- 33
- 44
- 34
Annual cashflow statement for Kalaris Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -69.8 | -172 | -169 | -190 | -58.8 |
| Depreciation | |||||
| Non-Cash Items | 9.93 | 46.1 | 42.1 | 63.5 | 16.4 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | -1.03 | 19.4 | -16.1 | 2.02 | -25.3 |
| Change in Accounts Receivable | |||||
| Change in Prepaid Expenses | |||||
| Change in Other Assets | |||||
| Change in Payable / Accrued Expenses | |||||
| Change in Taxes Payable | |||||
| Change in Other Liabilities | |||||
| Cash from Operating Activities | -60.8 | -106 | -142 | -124 | -67.7 |
| Capital Expenditures | -0.235 | -0.026 | 0 | — | — |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | -169 | 186 | -80.5 | 38 | 95 |
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Cash from Investing Activities | -169 | 186 | -80.5 | 38 | 95 |
| Financing Cash Flow Items | -3.47 | 0 | — | — | — |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Cash from Financing Activities | 292 | 0.232 | 127 | 70.5 | 0.021 |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 61.6 | 79.9 | -95.6 | -16 | 27.3 |